This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Almer, L. S. Articles by Shortridge, V. D. Search for Related Content PubMed PubMed Citation Articles by Almer, L. S. Articles by Shortridge, V. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2004, p. 2771-2777, Vol. 48, No. 7
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.7.2771-2777.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

In Vitro and Bactericidal Activities of ABT-492, a Novel Fluoroquinolone, against Gram-Positive and Gram-Negative Organisms

Laurel S. Almer,^* Jennifer B. Hoffrage, Erika L. Keller, Robert K. Flamm, and Virginia D. Shortridge

Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064-3537

Received 24 November 2003/ Returned for modification 22 February 2004/ Accepted 17 March 2004

In vitro activities of ABT-492, ciprofloxacin, levofloxacin, trovafloxacin, moxifloxacin, gatifloxacin, and gemifloxacin were compared. ABT-492 was more potent against quinolone-susceptible and -resistant gram-positive organisms, had activity similar to that of ciprofloxacin against certain members of the family Enterobacteriaceae, and had comparable activity against quinolone-susceptible, nonfermentative, gram-negative organisms. Bactericidal activity of ABT-492 was also evaluated.

Present address: St. Jude Children's Research Hospital, Nashville, TN 38105.

Present address: TAP Pharmaceuticals, Lake Forest, IL 60064.

Present address: Focus Technologies, Herndon, VA 20171.